Stock Performance Review on Biotech Industry -- Blueprint Medicines, Calithera Biosciences, Concordia Intl., and Cytokinetics

NEW YORK, August 14, 2017 /PRNewswire/ --

If you want a Stock Review on BPMC, CALA, CXRX, or CYTK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, the NASDAQ Composite ended the day at 6,256.56, up 0.64%; the Dow Jones Industrial Average edged 0.07% higher, to finish at 21,858.32; and the S&P 500 closed at 2,441.32, marginally gaining 0.13%. US markets saw a mixed session as 4 sectors closed in green, 4 sectors finished in red, and 1 sector ended flat for the day. DailyStockTracker.com has initiated research reports on the following Biotechnology stocks: Blueprint Medicines Corp. (NASDAQ: BPMC), Calithera Biosciences Inc. (NASDAQ: CALA), Concordia International Corp. (NASDAQ: CXRX), and Cytokinetics Inc. (NASDAQ: CYTK). Daily Stock Tracker published comprehensive and free research reports on these stocks today at:

http://dailystocktracker.com/register/

Blueprint Medicines 

Cambridge, Massachusetts headquartered Blueprint Medicines Corp.'s stock finished last Friday's session 1.81% lower at $46.11. A total volume of 304,564 shares was traded. The Company's shares have advanced 13.63% over the previous three months, 91.49% in the last twelve months, and 64.39% since the start of this year. The stock is trading above its 200-day moving average by 18.32%. Additionally, shares of Blueprint Medicines, which develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases, have a Relative Strength Index (RSI) of 39.3. BPMC complete research report is just a click away and free at:

http://dailystocktracker.com/registration/?symbol=BPMC

Calithera Biosciences 

On Friday, shares in South San Francisco, California headquartered Calithera Biosciences Inc. ended the session 15.35% higher at $13.90. The stock recorded a trading volume of 1.03 million shares, which was higher than its three months average volume of 840.65 thousand shares. The Company's shares have gained 351.30% over the past twelve months and 327.69% on an YTD basis. The stock is trading above its 200-day moving average by 40.62%. Moreover, shares of Calithera Biosciences, which focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the US, have an RSI of 43.29. The complimentary report on CALA can be downloaded at:

http://dailystocktracker.com/registration/?symbol=CALA

Concordia 

Oakville, Canada headquartered Concordia International Corp.'s shares declined 1.54%, closing the session at $1.28 with a total trading volume of 274,893 shares. The stock is trading below their 50-day moving average by 8.87%. Additionally, shares of Concordia International, which owns a portfolio of branded and generic prescription products in the US and internationally, have an RSI of 37.83. Sign up for your complimentary research report on CXRX at:

http://dailystocktracker.com/registration/?symbol=CXRX

Cytokinetics 

Last Friday at the close, shares in South San Francisco, California headquartered Cytokinetics Inc. recorded a trading volume of 629,882 shares, which was above their three months average volume of 521.95 thousand shares. The stock ended the session 1.25% higher at $12.15. The stock is trading below its 50-day moving average by 10.99%. Furthermore, shares of Cytokinetics, which focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining, have an RSI of 34.86.

On July 31^st, 2017, research firm Morgan Stanley initiated an 'Overweight' rating on the Company's stock, with a target price of $24 per share. Get free access to your research report on CYTK at:

http://dailystocktracker.com/registration/?symbol=CYTK

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA